

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT5937646

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT

**CONVEYING PARTY DATA**

Name	Execution Date
RECRO PHARMA, INC.	11/21/2019

**RECEIVING PARTY DATA**

<b>Name:</b>	BAUDAX BIO, INC.
<b>Street Address:</b>	490 LAPP ROAD
<b>City:</b>	MALVERN
<b>State/Country:</b>	PENNSYLVANIA
<b>Postal Code:</b>	19355

**PROPERTY NUMBERS Total: 36**

Property Type	Number
Application Number:	61178730
Application Number:	12781628
Application Number:	15424923
Application Number:	61293440
Application Number:	13520959
Application Number:	61466191
Application Number:	61569255
Application Number:	13711407
Application Number:	15702319
Application Number:	13096387
Application Number:	13925271
Application Number:	14738717
Application Number:	15239227
Application Number:	10537622
Application Number:	60004488
Application Number:	08696754
Application Number:	12027100
Application Number:	60353230
Application Number:	10357514
Application Number:	12292091

PATENT

Property Type	Number
Application Number:	13693858
Application Number:	60450705
Application Number:	10784900
Application Number:	13941076
Application Number:	15437534
Application Number:	15950367
Application Number:	15950539
Application Number:	16507796
Application Number:	16550239
Application Number:	62703094
Application Number:	62652656
Application Number:	16297095
Application Number:	62640232
Application Number:	16297020
Application Number:	62749407
Application Number:	62757003

#### CORRESPONDENCE DATA

**Fax Number:** (610)640-1965

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 6106512277

**Email:** chill@stradley.com

**Correspondent Name:** PAUL K. LEGAARD, ESQ.

**Address Line 1:** 30 VALLEY STREAM PARKWAY

**Address Line 2:** STRADLEY RONON STEVENS & YOUNG, LLP

**Address Line 4:** MALVERN, PENNSYLVANIA 19355-1481

<b>ATTORNEY DOCKET NUMBER:</b>	ASG-BAUDAX BIO, INC.
<b>NAME OF SUBMITTER:</b>	CATHERINE HILL
<b>SIGNATURE:</b>	/Cathy1/
<b>DATE SIGNED:</b>	01/30/2020

#### Total Attachments: 14

source=Assignment-BaudaxBioInc#page1.tif

source=Assignment-BaudaxBioInc#page2.tif

source=Assignment-BaudaxBioInc#page3.tif

source=Assignment-BaudaxBioInc#page4.tif

source=Assignment-BaudaxBioInc#page5.tif

source=Assignment-BaudaxBioInc#page6.tif

source=Assignment-BaudaxBioInc#page7.tif

source=Assignment-BaudaxBioInc#page8.tif

source=Assignment-BaudaxBioInc#page9.tif

source=Assignment-BaudaxBioInc#page10.tif  
source=Assignment-BaudaxBioInc#page11.tif  
source=Assignment-BaudaxBioInc#page12.tif  
source=Assignment-BaudaxBioInc#page13.tif  
source=Assignment-BaudaxBioInc#page14.tif

## EXHIBIT A

### **PATENT ASSIGNMENT AGREEMENT**

This PATENT ASSIGNMENT AGREEMENT ("Agreement") is made and entered into this 21st day of November, 2019 (the "Effective Date"), by and between Recro Pharma, Inc., a Pennsylvania corporation with an address of 490 Lapp Road, Malvern PA 19355 ("Assignor"), and Baudax Bio, Inc., a Pennsylvania company with an address of 490 Lapp Road, Malvern PA 19355 ("Assignee").

WHEREAS, Assignee and Assignor have entered that certain Asset Assignment and Assumption Agreement dated November 21, 2019 (the "Asset Assignment and Assumption Agreement") pursuant to which Assignor transferred, assigned, conveyed, granted and delivered to Assignee and Assignee accepted from Assignor certain Assigned Assets, including the Patents as defined in the Assignment and Assumption Agreement; and Assignee accepted such assignment.

WHEREAS, Assignor and Assignee desire to confirm and effectuate such assignment of the Patents pursuant to the terms and conditions set forth herein.

NOW THEREFORE, in consideration of the mutual covenants set forth herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, the parties hereby represent, covenant and agree as follows:

1. Defined Terms. Capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Asset Assignment and Assumption Agreement.

2. Assignment. Assignor does hereby irrevocably sell, assign, transfer, convey, grant and set over unto Assignee, its legal representatives, successors, and assigns, and Assignee does hereby accept such assignment, transfer, conveyance, grant and set over, Assignor's entire right, title and interest in and to (i) the national, regional and international patents and patent applications, including provisional patent applications, set forth on Schedule A attached hereto, including (ii) any and all patent applications filed either from such patents, patent applications or provisional applications or from an application claiming priority from any of these, including divisionals, continuations, continuations-in-part, substitutions, provisionals, converted provisionals, and continued prosecution applications, (iii) any and all patents that have issued or in the future issue from the patents and patent applications described in clauses (i) and/or (ii), including utility models, petty patents and design patents and certificates of invention and (iv) any and all extensions or restorations by existing or future extension or restoration mechanisms, including revalidations, reissues, re-examinations, supplemental examinations, inter partes reviews, post-grant reviews, oppositions and other existing or future post-issuance proceedings, and extensions (including future pending or issued unexpired patent term extension or supplemental protection certificate or equivalent extension right) of the patents or patent applications described in the foregoing clauses (i), (ii) and/or (iii); (v) any and all letters patent in the United States and all foreign countries which may be granted therefore and thereon; and (vi) all rights under the International Convention for the Protection of Industrial Property ((i) through

(vi), collectively, the "Assigned Patents"; and in each case of (i)-(vi), the same to be held and enjoyed by Assignee for its own use and benefit to the full end of the term for the Assigned Patents that may be granted or extended, as fully and entirely as the same would have been held and enjoyed by Assignor had this Agreement not been made, including all benefits, privileges, causes of action and remedies relating to, or otherwise derived from, such Assigned Patents, including the right to any damages accrued for infringement of the Assigned Patents prior to the date of this Agreement, the right to any extension, supplemental protection certificate or equivalent extension right (including the right to rely upon any activities of Assignor before any regulatory authority for purposes of obtaining any extension, supplemental protection certificate or equivalent extension right), and all goodwill associated with such Assigned Patents (all of the foregoing, including the Assigned Patents, the "Assigned Patent Rights"); and any and all intellectual property rights inherent in the Assigned Patent Rights and appurtenant thereto. Any assignment of rights shall be held and enjoyed by Assignee, its successors and assigns from and after the date of such assignment as fully and entirely as the same would have been held and enjoyed by Assignor had such assignment not been made.

3. Acceptance of Assignment. Assignee hereby accepts the assignment, transfer and conveyance of the rights and properties hereby assigned, transferred and conveyed to it herein.

4. Further Assurances. Upon said consideration, Assignor shall not execute any writing or do any act whatsoever conflicting with the terms and conditions of this Agreement, and that Assignor will, at any time upon request, without further or additional consideration, but at the expense of said Assignee, execute acknowledge and deliver, or cause to be executed, acknowledged and delivered, such additional instruments, notices, releases, certificates, powers of attorney, assurances, bills of sale, and other documents and do all such further acts, assignments, transfers and other things as said Assignee may deem necessary or desirable to perfect Assignee's enjoyment of this grant, and render all necessary assistance in making application for or obtaining original patents or applications, continuations, continuations-in-part, divisions, registrations, reissues, re-examinations or extensions thereof, whether in the U.S. or any foreign country, for said Assigned Patents, and in enforcing any rights or choses in action accruing as a result of such applications or patents, by giving testimony in any and all proceedings or transactions involving such applications or patents, and by executing preliminary statements and other affidavits, it being understood that the foregoing covenant and agreement shall bind and inure to the benefit of the assigns and legal representatives of Assignor and Assignee. The undersigned requests that any patents that may be issued for said Assigned Patents be issued to said Assignee, its legal representatives, successors or assigns, as an owner of my entire right, title and interest in and to said patent and the Assigned Patents covered thereby.

5. Recordation. Assignor hereby consents to and authorizes the United States Patent and Trademark Office or any other governmental office or agency in each jurisdiction other than the United States to record this Agreement and to issue any and all patents or certificates of invention which may be granted upon any of the Assigned Patents in the name of Assignee, as the assignee to the entire interest therein. Assignee shall have the right to file patent applications included in the Assigned Patents in any country.

6. Entire Agreement. This Agreement, together with the Asset Assignment and Assumption Agreement, constitutes the final agreement between the parties with respect to the subject matter contained herein, and is the complete and exclusive statement of the parties' agreement on the matters contained herein. All prior and contemporaneous negotiations and agreements between the parties with respect to the matters contained herein are superseded by this Agreement and the Asset Assignment and Assumption Agreement.

7. Amendments and Waiver. No modification, waiver or amendment of this Agreement shall be binding unless executed in writing by the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provision hereof unless otherwise expressly provided.

8. Binding Effect. This Agreement shall be binding upon and inure to the benefit of the respective successors and assigns of the parties hereto.

9. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware without regard to principles of conflicts of law.

10. Severability. If any provision of this Agreement shall be deemed invalid or unenforceable by any court of competent jurisdiction, then such portion shall be deemed severed, and the remainder thereof shall be enforceable in accordance with its terms.

11. Counterparts. This Agreement may be executed in two or more counterparts and by facsimile signature, each of which shall be deemed an original, but all of such counterparts together shall constitute one and the same instrument.

12. Successors and Assigns. This Agreement shall be binding on and inure to the benefit of the parties hereto, their successors in interest and assigns.

IN WITNESS WHEREOF, this Agreement has been duly executed by the undersigned as of the date set forth above.

**Recro Pharma, Inc.**

Assignor

By: GA Henwood  
Name: Gerri Henwood  
Title: President and Chief Executive Officer  
Date:  
Place:

On this 22 day of November, 2019, before me personally appeared Gerri Henwood of Recro Pharma, Inc., known to be the person named in and who executed the attached document, and acknowledged to me that she executed the same for the uses and purposes therein set forth.

SEAL


K J Hodge  
Notary Public

22 Nov 2019  
Date

My commission expires 02/22/2023


COMMONWEALTH OF PENNSYLVANIA - NOTARY SEAL  
Kenneth J Hodge, Notary Public  
Chester County  
My Commission Expires 02/22/2023  
Commission Number 1347292


**Baudax Bio, Inc.**  
Assignee

By:   
Name: Ryan Lake  
Title: Chief Financial Officer and Treasurer  
Date:  
Place:

On this 22 day of November, 2019, before me personally appeared Ryan Lake of Baudax Bio, Inc., known to be the person named in and who executed the attached document, and acknowledged to me that he executed the same for the uses and purposes therein set forth.

SEAL



  
Notary Public

22 Nov 2019  
Date

My commission expires 02/22/2023



**SCHEDULE A**

<b>Country</b>	<b>Serial No. Pub. No. Patent No.</b>	<b>Filing Date Pub. Date Issue Date</b>	<b>Title</b>
United States	61/178,730	5/15/09	Sublingual Dexmedetomidine Spray Compositions And Methods Of Use Thereof
United States	12/781,628 2011-0021588	5/17/10 1/27/11	Oral Mucosal Dexmedetomidine Compositions And Methods Of Use Thereof
United States	15/424,923	2/6/17	Oral Mucosal Dexmedetomidine Compositions And Methods Of Use Thereof
PCT	PCT/US10/35136 WO 10/132882 WO 10/132882 WO 10/132882	5/17/10 11/18/10 3/31/11 12/29/11	Sublingual Dexmedetomidine Compositions And Methods Of Use Thereof
Europe	10775671.0 EP2429521 EP2429521	5/17/10 3/21/12 10/18/17	Sublingual Dexmedetomidine Compositions And Methods Of Use Thereof
Europe	17187813.5 EP3305281	8/24/17 4/11/18	Sublingual Dexmedetomidine Compositions And Methods Of Use Thereof
Japan	2012-511068 2012-526854 6172938	11/14/11 11/1/12 7/14/17	Sublingual Dexmedetomidine Compositions And Methods Of Use Thereof
Japan	2015-179975 2016-029055	9/11/15 3/3/16	Sublingual Dexmedetomidine Compositions And Methods Of Use Thereof
Australia	2010248776 2010248776	5/17/10 9/19/13	Sublingual Dexmedetomidine Spray Compositions And Methods Of Use Thereof
Brazil	PI 1010567-0 2358	11/16/11 3/15/16	Sublingual Dexmedetomidine Spray Compositions And Methods Of Use Thereof
Canada	2,762,107	11/15/11	Sublingual Dexmedetomidine Compositions And Methods Of Use Thereof
Chile	02858-2011 Published	11/14/11 6/22/12	Sublingual Dexmedetomidine Spray Compositions And Methods Of Use Thereof
China	201080021182.0 CN102639131A	11/15/11 8/15/12	Sublingual Dexmedetomidine Spray Compositions And Methods Of Use Thereof
Colombia	11-155150 767	11/15/11 6/15/12	Oral, Transmucoasl Pharmaceutical Composition Comprising Dexmedetomidine
Costa Rica	2011-0596	11/14/11	Sublingual Dexmedetomidine Spray Compositions And Methods Of Use Thereof
Dominican Republic	P2011-0354 Published	11/14/11 7/15/12	Sublingual Dexmedetomidine Spray Compositions And Methods Of Use Thereof
Ecuador	SP-11-11459 Pub	11/14/11 1/31/12	Sublingual Dexmedetomidine Spray Compositions And Methods Of Use Thereof
Egypt	1927/2011	11/14/11	Sublingual Dexmedetomidine Spray Compositions And Methods Of Use Thereof
Honduras	2011-003011 5656	11/14/11 5/6/15	Sublingual Dexmedetomidine Spray Compositions And Methods Of Use Thereof
India	9629/DELNP/2011 P2011-0354	8/12/11 7/15/12	Sublingual Dexmedetomidine Compositions And Methods Of Use Thereof

Country	Serial No. Pub. No. Patent No.	Filing Date Pub. Date Issue Date	Title
Indonesia	W00201104163 2014/04461 IDP000049660	11/14/11 11/6/14 2/15/18	Sublingual Dexmedetomidine Spray Compositions And Methods Of Use Thereof
Israel	216159 216159	11/6/11 1/30/16	Oral Transmucosal Dexmedetomidine Compositions, Delivery Device Comprising The Same And Use Thereof In The Preparation Of Medicaments For Treating Pain Without Sedation
South Korea	10-2011-7027466 10-1859486	11/18/11 5/14/18	Sublingual Dexmedetomidine Spray Compositions And Methods Of Use Thereof
Mexico	2011/011950 333985	11/10/11 10/13/15	Sublingual Dexmedetomidine Spray Compositions And Methods Of Use Thereof
New Zealand	596976 596976	12/8/11 9/2/14	Sublingual Dexmedetomidine Spray Compositions And Methods Of Use Thereof
Peru	1958-2011 1958-2011	11/14/11 7/8/12	Sublingual Dexmedetomidine Spray Compositions And Methods Of Use Thereof
Philippines	1-2011-502387	11/15/11	Sublingual Dexmedetomidine Spray Compositions And Methods Of Use Thereof
Russia	2011151059 2011151059 2572692	12/14/11 6/20/13 12/14/15	Sublingual Dexmedetomidine Spray Compositions And Methods Of Use Thereof
Singapore	201108266-6 175979	11/9/11 9/23/14	Sublingual Dexmedetomidine Compositions And Methods Of Use Thereof
Viet Nam	1-2011-03095 29430	11/14/11 4/25/12	Sublingual Dexmedetomidine Compositions And Methods Of Use Thereof
South Africa	2011/08359 2011/08359	11/14/11 7/25/12	Sublingual Dexmedetomidine Compositions And Methods Of Use Thereof
Hong Kong	12109245.0 1168302	9/20/12 5/4/18	Sublingual Dexmedetomidine Compositions And Methods Of Use Thereof
China	201610753813.7 CN 106511273A	8/29/16 3/22/17	Sublingual Dexmedetomidine Spray Compositions And Methods Of Use Thereof
Germany	EP2429521	10/18/17	Sublingual Dexmedetomidine Compositions And Methods Of Use Thereof
France	EP2429521	10/18/17	Sublingual Dexmedetomidine Compositions And Methods Of Use Thereof
Great Britain	EP2429521	10/18/17	Sublingual Dexmedetomidine Compositions And Methods Of Use Thereof
Ireland	EP2429521	10/18/17	Sublingual Dexmedetomidine Compositions And Methods Of Use Thereof
United States	61/293,440	1/8/10	Topical Transdermal Dexmedetomidine Compositions and Methods of Use Thereof
United States	13/520,959	12/3/12	Topical Transdermal Dexmedetomidine Compositions and Methods of Use Thereof
PCT	PCT/US11/020462	1/7/11	Topical Transdermal Dexmedetomidine Compositions and Methods of Use Thereof
Europe	11732180.2	1/7/11	Topical Transdermal Dexmedetomidine Compositions and Methods of Use Thereof
Japan	2012-548137	1/7/11	Topical Transdermal Dexmedetomidine Compositions and Methods of Use Thereof

Country	Serial No. Pub. No. Patent No.	Filing Date Pub. Date Issue Date	Title
Australia	2011204315	1/7/11	Topical Transdermal Dexmedetomidine Compositions and Methods of Use Thereof
Canada	2,786,598	1/7/11	Topical Transdermal Dexmedetomidine Compositions and Methods of Use Thereof
China	20118008886.9	1/7/11	Topical Transdermal Dexmedetomidine Compositions and Methods of Use Thereof
Mexico	MX/A/2012/007933	1/7/11	Topical Transdermal Dexmedetomidine Compositions and Methods of Use Thereof
New Zealand	601195	1/7/11	Topical Transdermal Dexmedetomidine Compositions and Methods of Use Thereof
Russia	2012133969	1/7/11	Topical Transdermal Dexmedetomidine Compositions and Methods of Use Thereof
Hong Kong	13105662.1	1/7/11	Topical Transdermal Dexmedetomidine Compositions and Methods of Use Thereof
New Zealand	703808	1/7/11	Topical Transdermal Dexmedetomidine Compositions and Methods of Use Thereof
United States	61/466,191	3/22/11	A Double-Blind Placebo Controlled, Crossover Evaluation of the Analgesic Effects of REC1100 in Chronic Low Back Pain Patients
United States	61/569,255	12/11/11	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof
United States	13/711,407 2013-0178465 9,795,559	12/11/12 7/11/13 10/24/17	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof
United States	15/702,319 2018-0055764	9/12/17 3/1/18	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof
PCT	PCT/US12/68988 WO 13/090278 WO 13/090278	12/11/12 6/20/13 12/24/14	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof
Europe	12857098.3 EP2787970 EP2787970	12/11/12 10/15/14 4/11/18	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof
Europe	18161834.9 EP3406247	3/14/18 11/28/18	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof
Japan	2014-546186 2015-513309 6268100	6/10/14 5/7/15 1/5/18	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof
Japan	2017-172633 2018-030850 6505177	9/8/17 3/1/18 4/24/19	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof
Australia	2012352528 2012352528	12/11/12 2/8/18	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof
Brazil	BR1120140191719	6/9/14	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof
Canada	2,858,721	6/9/14	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof
Chile	2014-01515 700	6/9/14 7/21/14	Use Of 10 µg To 50 µg Of Dexmedetomidine, Or A Pharmaceutically Acceptable Salt Thereof For Preparing An Intranasal Medicament For Treating Or Preventing Pain In An Adult Human

Country	Serial No. Pub. No. Patent No.	Filing Date Pub. Date Issue Date	Title
China	201280067920.4 CN 104470516	7/23/14 3/25/15	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof
Colombia	14-143289	7/3/14	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof
Costa Rica	2014-0318	7/3/14	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof
Dominican Republic	P2014-0123	6/9/14	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof
Ecuador	IEPI 2014-7644 609	7/3/14	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof
Egypt	916/2014 PCT	6/9/14	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof
Honduras	2014-000880	6/9/14	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof
India	5403/2014	7/1/14	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof
Indonesia	P00 2014 03910 2015/05287	6/27/14 11/27/15	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof
Israel	232977 232977	6/5/14 5/1/19	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof
South Korea	10-2014-7017624	12/11/12	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof
Mexico	2014/006961 367286	6/10/14 8/13/19	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof
New Zealand	626999 626999	12/11/12 11/1/16	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof
Peru	924-2014	6/9/14	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof
Philippines	1-2014-501273	6/5/14	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof
Russia	2014128343 2014128343 2692245	7/10/14 1/27/16	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof
Singapore	11201403094T	6/10/14	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof
Viet Nam	1-2014-02131	6/30/14	Intranasal Dexmedetomidine Pharmaceutical Compositions And Metered Dose Devices Comprising The Same
South Africa	2014/04287	6/10/14	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof
Hong Kong	15103572.3 1203049 1203049	4/13/15 10/16/15 5/17/19	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof
Singapore	10201604653T	6/8/16	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof
Australia	2018200591 2018200591	1/24/18 3/14/19	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof
Germany	EP2787970	4/11/18	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof

Country	Serial No. Pub. No. Patent No.	Filing Date Pub. Date Issue Date	Title
France	EP2787970	4/11/18	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof
Great Britain	EP2787970	4/11/18	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof
Ireland	EP2787970	4/11/18	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof
Italy	EP2787970	4/11/18	Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof
United States	13/096,387 2011-0294862 8,470,862	4/28/11 12/1/11 6/25/13	Treatment Or Prevention Of Hypotension And Shock
United States	13/925,271 2014-0100257 9,078,883	6/24/13 4/10/14 7/14/15	Treatment Or Prevention Of Hypotension And Shock
United States	14/738,717 2016-0030392 9,446,025	6/12/15 2/4/16 9/20/16	Treatment Or Prevention Of Hypotension And Shock
United States	15/239,227	8/17/16	Treatment Or Prevention Of Hypotension And Shock
United States	10/537,622 2006-0178417 7,759,496	3/29/06 8/10/06 7/20/10	Imidazol Derivatives Having Affinity For Alpha 2 Receptors Activity
Japan	2004-556387 4667042	12/5/03 1/21/11	Imidazol Derivatives Having Affinity For Alpha 2 Receptors Activity
Australia	2003302622 2003302622	12/5/03 5/27/10	Imidazol Derivatives Having Affinity For Alpha 2 Receptors Activity
Canada	2,508,335 2,508,335	12/5/03 9/13/11	Imidazol Derivatives Having Affinity For Alpha 2 Receptors Activity
China	200380105132.0 1735409 200380105132.0	12/5/03 2/15/06 11/18/09	Imidazol Derivatives Having Affinity For Alpha 2 Receptors Activity
Israel	168882 168882	12/5/03 9/1/10	Imidazol Derivatives Having Affinity For Alpha 2 Receptors Activity
Mexico	2005/005963 253821	12/5/03 1/25/08	Imidazol Derivatives Having Affinity For Alpha 2 Receptors Activity
New Zealand	540466 540466	12/5/03 8/14/08	Imidazol Derivatives Having Affinity For Alpha 2 Receptors Activity
Philippines	1-2005-501062 1-2005-501062	12/5/03 12/4/09	Imidazol Derivatives Having Affinity For Alpha 2 Receptors Activity
Singapore	200503419.4 111885	12/5/03 6/29/07	Imidazol Derivatives Having Affinity For Alpha 2 Receptors Activity
South Africa	2005/04533 2005/04533	12/5/03 3/29/06	Imidazol Derivatives Having Affinity For Alpha 2 Receptors Activity
Germany	EP1572198	4/19/06	Imidazol Derivatives Having Affinity For Alpha 2 Receptors Activity
Spain	EP1572198	4/19/06	Imidazol Derivatives Having Affinity For Alpha 2 Receptors Activity

Country	Serial No. Pub. No. Patent No.	Filing Date Pub. Date Issue Date	Title
France	EP1572198	4/19/06	Imidazol Derivatives Having Affinity For Alpha 2 Receptors Activity
Great Britain	EP1572198	4/19/06	Imidazol Derivatives Having Affinity For Alpha 2 Receptors Activity
Ireland	EP1572198	4/19/06	Imidazol Derivatives Having Affinity For Alpha 2 Receptors Activity
United States	60/004,488	9/29/95	Reduction of Intravenously Administered Nanoparticulate-Formulation Induced Adverse Physiological Reactions
United States	08/696,754 5,834,025	8/14/96 11/10/98	Reduction of Intravenously Administered Nanoparticulate-Formulation Induced Adverse Physiological Reactions
Europe	10181619.7	9/25/96	Reduction of Intravenously Administered Nanoparticulate-Formulation Induced Adverse Physiological Reactions
Canada	2,232,879 2,232,879	9/25/96 3/2/04	Reduction of Intravenously Administered Nanoparticulate-Formulation Induced Adverse Physiological Reactions
United States	12/027,100 RE41884	2/6/08 10/26/10	Reduction of Intravenously Administered Nanoparticulate-Formulation Induced Adverse Physiological Reactions
Europe	96932321.1	9/25/96	Reduction of Intravenously Administered Nanoparticulate-Formulation Induced Adverse Physiological Reactions
United States	60/353,230	2/4/02	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer
United States	10/357,514 2003-0185869 7,459,283	2/4/03 10/2/03 12/2/08	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer
United States	12/292,091 2009-0074875 8,323,641	11/12/08 3/19/09 12/4/12	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer
United States	13/693,858 2013-0224123 8,652,464	12/4/12 8/29/13 2/18/14	Method Of Treatment Uisng Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer
Europe	03737537.5 EP1471887	2/4/03 4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer
Japan	2003-565446 4598399	2/4/03 4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer
Japan (divisional)	2003-565446	2/4/03	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer
Canada	2,475,092 2,475,092	2/4/03 5/1/12	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer
Austria	EP1471887	4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer
Belgium	EP1471887	4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer
Bulgaria	EP1471887	4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer

Country	Serial No. Pub. No. Patent No.	Filing Date Pub. Date Issue Date	Title
Czech Republic	EP1471887	4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer
Denmark	EP1471887	4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer
Finland	EP1471887	4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer
France	EP1471887	4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer
Germany	EP1471887	4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer
Greece	EP1471887	4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer
Hungary	EP1471887	4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer
Ireland	EP1471887	4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer
Italy	EP1471887	4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer
Netherlands	EP1471887	4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer
Portugal	EP1471887	4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer
Slovakia	EP1471887	4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer
Spain	EP1471887	4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer
Sweden	EP1471887	4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer
Switzerland	EP1471887	4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer
Great Britain	EP1471887	4/21/10	Nanoparticulate Compositions Having Lysozyme As A Surface Stabilizer
United States	60/450,705	3/3/03	Nanoparticulate Meloxicam Formulations
United States	10/784,900 2004-0229038 8,512,727	2/24/04 11/18/04 8/20/13	Nanoparticulate Meloxicam Formulations
United States	13/941,076 2014-0141083	7/12/13 5/22/14	Nanoparticulate Meloxicam Formulations
United States	15/437,534 2017-0157061 10,471,067	2/21/17 6/8/17 11/12/19	Nanoparticulate Meloxicam Formulations
United States	15/950,367 2018-0228809 10,463,673	4/11/18 8/16/18 11/5/19	Nanoparticulate Meloxicam Formulations
United States	15/950,539 2018-0228810	4/11/18 8/16/18	Nanoparticulate Meloxicam Formulations
United States	16/507,796	7/10/19	Nanoparticulate Meloxicam Formulations
United States	16/550,239 2019-0381062	8/25/19 12/19/19	Nanoparticulate Meloxicam Formulations
Europe	04785761.0	2/27/04	Nanoparticulate Meloxicam Formulations

**PATENT**

**REEL: 051671 FRAME: 0550**

Country	Serial No. Pub. No. Patent No.	Filing Date Pub. Date Issue Date	Title
	EP1617816	5/13/09	
Europe	08006465.2	2/27/04	Nanoparticulate Meloxicam Formulations
Europe	16161176.9 EP3090731 EP3090731	3/18/16 11/9/16 9/19/18	Nanoparticulate Meloxicam Formulations
Europe	18186018.0 EP3434261	7/27/18 1/30/19	Nanoparticulate Meloxicam Formulations
Japan	2006-532300 4891774	2/27/04 12/22/11	Nanoparticulate Meloxicam Formulations
Japan	2010-233858 5548092	2/27/04 7/16/14	Nanoparticulate Meloxicam Formulations
Japan	2011-148037 2012-012397	7/4/11 1/19/12	Nanoparticulate Meloxicam Formulations
Canada	2,517,679 2,517,679	2/27/04 4/10/12	Nanoparticulate Meloxicam Formulations
Belgium	EP1617816	5/13/09	Nanoparticulate Meloxicam Formulations
France	EP1617816	5/13/09	Nanoparticulate Meloxicam Formulations
Germany	EP1617816	5/13/09	Nanoparticulate Meloxicam Formulations
Hungary	EP1617816	5/13/09	Nanoparticulate Meloxicam Formulations
Ireland	EP1617816	5/13/09	Nanoparticulate Meloxicam Formulations
Italy	EP1617816	5/13/09	Nanoparticulate Meloxicam Formulations
Spain	EP1617816	5/13/09	Nanoparticulate Meloxicam Formulations
Switzerland	EP1617816	5/13/09	Nanoparticulate Meloxicam Formulations
Great Britain	EP1617816	5/13/09	Nanoparticulate Meloxicam Formulations
Hong Kong	17102503.7 1228765A HK1228765	3/10/17 11/10/17 10/11/19	Nanoparticulate Meloxicam Formulations
Austria	EP3090731	9/19/18	Nanoparticulate Meloxicam Formulations
Belgium	EP3090731	9/19/18	Nanoparticulate Meloxicam Formulations
Denmark	EP3090731	9/19/18	Nanoparticulate Meloxicam Formulations
Finland	EP3090731	9/19/18	Nanoparticulate Meloxicam Formulations
France	EP3090731	9/19/18	Nanoparticulate Meloxicam Formulations
Germany	EP3090731	9/19/18	Nanoparticulate Meloxicam Formulations
Hungary	EP3090731	9/19/18	Nanoparticulate Meloxicam Formulations
Ireland	EP3090731	9/19/18	Nanoparticulate Meloxicam Formulations
Italy	EP3090731	9/19/18	Nanoparticulate Meloxicam Formulations
Spain	EP3090731	9/19/18	Nanoparticulate Meloxicam Formulations
Sweden	EP3090731	9/19/18	Nanoparticulate Meloxicam Formulations
Switzerland	EP3090731	9/19/18	Nanoparticulate Meloxicam Formulations
Netherlands	3090731	9/19/18	Nanoparticulate Meloxicam Formulations
Great Britain	EP3090731	9/19/18	Nanoparticulate Meloxicam Formulations
Hong Kong	19127168.3	7/23/19	Nanoparticulate Meloxicam Formulations
United States	62/703,094	7/25/18	Highly Concentrated Meloxicam Compositions
United States 189109.02600			Highly Concentrated Meloxicam Formulations



Country	Serial No. Pub. No. Patent No.	Filing Date Pub. Date Issue Date	Title
United States	62/652,656	4/4/18	Methods Of Administering Intravenous Meloxicam In A Bolus Dose
United States	16/297,095	3/8/19	Methods Of Administering Intravenous Meloxicam In A Bolus Dose
PCT	PCT/US19/021354	3/8/19	Methods Of Administering Intravenous Meloxicam In A Bolus Dose
United States	62/640,232	3/8/18	Method Of Treating Pain In Elderly Patients With Mild Renal Impairment
United States	16/297,020	3/8/19	Method Of Treating Pain In Elderly Patients With Mild Renal Impairment
United States	62/749,407	10/23/18	Methods Of Administering Intravenous Meloxicam Pre-Operatively And In Combination With Other Drugs
PCT	PCT/US19/57692	10/23/19	Methods Of Administering Intravenous Meloxicam Pre-Operatively And In Combination With Other Drugs
United States	62/757,003	11/7/18	Methods Of Treating Patients Having Platelet Dysfunction With IV Meloxicam
PCT	PCT/US19/60278	11/7/19	Methods Of Treating Patients Having Platelet Dysfunction With IV Meloxicam